Seeing is believing: Anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy

Signal Transduction and Targeted Therapy

Volumn 1, Issue , 2016, Pages

  Tan, Shuguang ^a   Zhang, Catherine W H ^b   Gao, George F ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b Cellbiotech Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85011708128     PISSN: 20959907     EISSN: 20593635     Source Type: Journal    
DOI: 10.1038/sigtrans.2016.29     Document Type: Article

References (42)

1. Harrison SC. Don C. Wiley (1944-2001). Cell 2002; 108: 313–315.
2. Chen Y, Shi Y, Cheng H, An YQ, Gao GF. Structural immunology and crystallography help immunologists see the immune system in action: how T and NK cells touch their ligands. IUBMB Life 2009; 61: 579–590.
3. Du J, Cross TA, Zhou HX. Recent progress in structure-based anti-influenza drug design. Drug Discov Today 2012; 17: 1111–1120.
4. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Ann Rev Immunol 2004; 22: 247–306.
5. Wu Y, Bi Y, Vavricka CJ, Sun X, Zhang Y, Gao F et al. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res 2013; 23: 1347–1355.
6. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432–1433.
7. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970; 169: 1042–1049.
8. Cunningham AJ, Lafferty KJ. A simple conservative explanation of the H-2 restriction of interactions between lymphocytes. Scand J Immunol 1977; 6: 1–6.
9. Gao GF, Tormo J, Gerth UC, Wyer JR, McMichael AJ, Stuart DI et al. Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2. Nature 1997; 387: 630–634.
10. Gao GF, Jakobsen BK. Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunol Today 2000; 21: 630–636.
11. Gao GF, Rao Z, Bell JI. Molecular coordination of alphabeta T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands. Trends Immunol 2002; 23: 408–413.
12. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975; 53: 27–42.
13. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of Pd-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell-death. EMBO J 1992; 11: 3887–3895.
14. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. JExpMed 2000; 192: 1027–1034.
15. Latchman YWC, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2: 261–268.
16. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A et al. Coregulation of CD8(+) T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29–37.
17. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006; 119: 317–327.
18. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293–12297.
19. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S et al. Aberrant PD-L1 expression through 3 '-UTR disruption in multiple cancers. Nature 2016; 534: 402-+.
20. Curiel TJ, Wei S, Dong HD, Alvarez X, Cheng P, Mottram P et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562–567.
21. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015–3029.
22. Tan S, Gao GF. New hope for cancer treatment: cancer Immunotherapy. Chinese Sci Bull 2015; 60: 3155–3157 (in Chinese).
23. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004; 20: 107–118.
24. Callahan MK, Postow MA, Wolchok JD, Targeting T. Cell co-receptors for cancer therapy. Immunity 2016; 44: 1069–1078.
25. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006–2017.
26. Chapman PB, D'Angelo SP, Wolchok JD. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N Engl J Med 2015; 372: 2073–2074.
27. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558–562.
28. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372: 2521–2532.
29. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov 2015; 5: 1282–1295.
30. Liu K, Tan S, Chai Y, Chen D, Song H, Zhang CW et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res 2016; e-pub ahead of print 30 August 2016; doi:10.1038/cr.2016.102.
31. Na Z, Yeo SP, Bharath SR, Bowler MW, Balikci E, Wang CI et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res 2016; e-pub ahead of print 21 June 2016; doi:10.1038/cr.2016.77
32. Tan S, Chen D, Liu K, He M, Song H, Shi Y et al. Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell 2016; e-pub ahead of print 4 November 2016; doi:10.1007/s13238-016-0337-7.
33. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111–122.
34. Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 2013; 288: 11771–11785.
35. Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201–210.
36. Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 2010; 10: 255–265.
37. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167–3175.
38. Simpson TR, Li FB, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210: 1695–1710.
39. Lazar-Molnar E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci USA 2008; 105: 10483–10488.
40. Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci USA 2008; 105: 3011–3016.
41. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 2015; 23: 2341–2348.
42. Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA 2015; 112: E6506–E6514.